Inovio Pharmaceuticals, Inc. (INO) is a NASDAQ listed company with a market capitalization of 381.7 mln USD. Over the last six quarters, the company’s financial performance has been volatile as evident from its revenue figures. According to the available information, Inovio reported a revenue of 0 USD in the quarter ending December 31st 2022, 915.4 thousand USD in the quarter ending September 30th 2022 and 199.07 mln USD in the quarter ending March 31st 2022. The highest reported revenue figure was 839.12 mln USD in the quarter ending December 31st 2021 while the lowest was 0 USD in the quarter ending June 30th 2022.
Overall, Inovio’s revenue figures indicate an inconsistent financial performance over time due to unpredictable market conditions and changes in consumer behaviour. The company projected a revenue of 340 thousand USD for its current quarter which is lower than its average quarterly revenue of 467 million dollars over past two years. This suggests that Inovo could be facing tough times financially and may need to look for other ways to increase its revenues such as introducing new products or services or expanding into new markets.
